PMID- 27996286
OWN - NLM
STAT- MEDLINE
DCOM- 20190627
LR  - 20190627
IS  - 0125-877X (Print)
IS  - 0125-877X (Linking)
VI  - 35
IP  - 3
DP  - 2017 Sep
TI  - Safety and efficacy of ant rush immunotherapy in children.
PG  - 156-160
LID - 10.12932/AP0831 [doi]
AB  - BACKGROUND: The Rush Immunotherapy (RIT) protocol is a valid alternative in order 
      to reach the maintenance phase early. However, there are scarce studies in the 
      literature that have evaluated the safety and the efficacy of an ant RIT process 
      in children. OBJECTIVE: To evaluate the safety and the efficacy of an ant RIT 
      protocol and to identify the risk factors for systemic reactions (SRs) during an 
      RIT procedure in children. METHOD: A retrospective review was conducted for those 
      children who were receiving an ant RIT procedure. The 3-day RIT protocol 
      consisted of hourly subcutaneous injections in order to achieve a 0.5 ml 
      maintenance dose of a 1:100 weight/ volume (wt/vol) of the Solenopsis invicta 
      whole body extract. The safety for an RIT procedure was monitored by using the 
      World Allergy Organization Subcutaneous Immunology Systemic Reaction Grading 
      System. The efficacy was assessed by the reactions after a field ant re-sting. 
      RESULT: A total of 20 children who were receiving an ant RIT therapy were 
      reviewed. The mean age was 9.5+/-3.07 years. There were 6 systemic reactions (SRs) 
      from 324 injections during the RIT procedure (1.85%). All of the systemic 
      reactions were Grade 1-2. There were no associations of SRs regarding age, 
      gender, an atopic history, or the levels of immunoglobulin E (IgE) sensitization 
      to the ants. Among the 14 patients who experienced a field ant re-sting, 4 
      (28.5%) patients developed Grade 3 SRs. These Grade 3 reactions were resolved 
      after an increase of the maintenance dose to 0.5 ml of a 1:50 wt/vol. There was a 
      significant difference in the mean age of those children who had ant re-sting 
      systemic reactions and those who had no reactions (6.75+/-0.95 year vs. 10.8+/-3.29, 
      p=0.036). CONCLUSION: Rush immunotherapy with ant in children is safe and it has 
      a low occurrence of severe systemic reactions. It is an alternative treatment for 
      those patients requiring a rapid protection.
FAU - Manuyakorn, Wiparat
AU  - Manuyakorn W
AD  - Division of Pediatrics Allergy and Immunology, Department of Pediatrics, Faculty 
      of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
FAU - Benjaponpitak, Suwat
AU  - Benjaponpitak S
AD  - Division of Pediatrics Allergy and Immunology, Department of Pediatrics, Faculty 
      of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
FAU - Kamchaisatian, Wasu
AU  - Kamchaisatian W
AD  - Division of Pediatrics Allergy and Immunology, Department of Pediatrics, Faculty 
      of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
FAU - Sasisakulporn, Cherapat
AU  - Sasisakulporn C
AD  - Division of Pediatrics Allergy and Immunology, Department of Pediatrics, Faculty 
      of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
FAU - Jotikasthira, Wanlapa
AU  - Jotikasthira W
AD  - Division of Pediatrics Allergy and Immunology, Department of Pediatrics, Faculty 
      of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
LA  - eng
PT  - Journal Article
PL  - Thailand
TA  - Asian Pac J Allergy Immunol
JT  - Asian Pacific journal of allergy and immunology
JID - 8402034
RN  - 0 (Allergens)
RN  - 0 (Biomarkers)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Adolescent
MH  - Allergens/*immunology
MH  - Animals
MH  - Ants/*immunology
MH  - Biomarkers
MH  - Child
MH  - *Desensitization, Immunologic/adverse effects/methods
MH  - Female
MH  - Humans
MH  - Immunoglobulin E/blood/immunology
MH  - Insect Bites and Stings/diagnosis/*etiology/*therapy
MH  - Male
MH  - Skin Tests
EDAT- 2016/12/21 06:00
MHDA- 2019/06/30 06:00
CRDT- 2016/12/21 06:00
PHST- 2016/12/21 06:00 [pubmed]
PHST- 2019/06/30 06:00 [medline]
PHST- 2016/12/21 06:00 [entrez]
AID - 10.12932/AP0831 [doi]
PST - ppublish
SO  - Asian Pac J Allergy Immunol. 2017 Sep;35(3):156-160. doi: 10.12932/AP0831.